drugset / Trial / NCT00492050
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
Phase 2
Active not recruiting
46 enrolled
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The main goal of this clinical research study is to learn if Velcade ® (bortezomib) given with rituximab can help to control WM. This drug combination will allow researchers to collect your stem cells in case it is possible to transplant the stem cells as treatment if your WM gets worse. Researchers will also look at the safety and tolerability of this drug combination followed by treatment with other drug combinations.
Timeline
- Start
- 2006-08-02
- Primary completion
- 2021-02-28
- Completion
- 2026-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | Acyclovir | Small molecule | 200 mg | Oral |
| Background | Valacyclovir | Unknown | 500 mg | Oral |